Marinus Pharmaceuticals | SC TO-C:投标报价书面通信
Marinus Pharmaceuticals | SC14D9C:报价书面通信
Marinus Pharmaceuticals | 8-K:重大事件
Marinus Pharmaceuticals | 8-K:重大事件
Marinus Pharmaceuticals | 8-K:重大事件
Marinus Pharmaceuticals | 8-K:重大事件
Marinus Pharmaceuticals | 144:拟议出售证券
Marinus Pharmaceuticals | 8-K:重大事件
Marinus Pharmaceuticals | SC 13G:超过5%持股股东披露文件-Sofinnova Investments, Inc.(8.0%),James Healy(8.0%)等
Marinus Pharmaceuticals | SC 13G/A:超过5%持股股东披露文件(修正)-Cormorant Asset Management, LP(0%),Bihua Chen(0%)
Marinus Pharmaceuticals | SC 13G/A:超过5%持股股东披露文件(修正)-Eventide Asset Management, LLC(0.00%),Finny Kuruvilla, M.D. Ph. D.(0.00%)等
Marinus Pharmaceuticals | SC 13G/A:超过5%持股股东披露文件(修正)
Marinus Pharmaceuticals | SC 13G/A:超过5%持股股东披露文件(修正)-Avoro Capital Advisors LLC(0%),Behzad Aghazadeh(0%)
Marinus Pharmaceuticals | 8-K:Marinus Pharmicals提供最新业务并报告2024年第三季度财务业绩
Marinus Pharmaceuticals | 10-Q:2024财年三季报
Marinus Pharmaceuticals | SC 13G/A:超过5%持股股东披露文件(修正)-The Vanguard Group(5.08%)
Marinus Pharmaceuticals | SC 13G/A:超过5%持股股东披露文件(修正)-Jennison Associates LLC(0%)
Marinus Pharmaceuticals | SC 13G/A:超过5%持股股东披露文件(修正)-The Vanguard Group(5.08%)
Marinus Pharmaceuticals | SC 13G:超过5%持股股东披露文件-Panacea Innovation Limited(9.98%),Panacea Venture Healthcare Fund II, L.P.(9.98%)等
Marinus Pharmaceuticals | SCHEDULE 13G/A:其他